Myriad Genetics, Inc. (MYGN)'s Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients
6/4/2012 9:57:49 AM
SALT LAKE CITY, June 4, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2012 at the American Society of Clinical Oncology® (ASCO) Annual Meeting in Chicago. The study demonstrates that the Company's lung cancer prognosis test significantly predicts cancer-specific death in early stage adenocarcinoma lung cancer patients.
comments powered by